The Latest Cardiac and Vascular News
Company continues to make progress on its potential treatment for PAD, a disease affecting 200 million people worldwide LAS VEGAS, Sept. 24, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has started […]
Company pursuing additional application for JAN101 to treat COVID-19 complications Stable formulation and engineering for JAN101 will support Phase 2b PAD Study under the FDA’s Investigational New Drug (IND) #111703, expected to begin the first quarter of 2021 Scientific Advisory Board bolstered by expert additions LAS VEGAS, Sept. 22, 2020 /PRNewswire/ — JanOne […]
Update on plans for sale of recycling business. Divesting will allow for focus on core life science assets LAS VEGAS, Sept. 16, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, provided an update today regarding its initiatives […]
Bottling and labeling partner Eurofins CDMO (Alphora Research, Inc.) to ensure JanOne clinical research maintains compliance with GMP and FDA regulations LAS VEGAS, Sept. 3, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability […]
Engineering batch for JAN101 complete and expectations are for GMP batch production to begin within 30 days LAS VEGAS, Aug. 26, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has successfully completed its initial engineering batch […]
JAN101 formulation ready for Phase 2b peripheral artery disease trials and for potential treatment of COVID-19 vascular inflammation LAS VEGAS, Aug. 11, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, together with its manufacturing partner, […]
Study to Explore JAN101’s Potential to Treat Ischemia¹ and Endothelial dysfunction² in COVID-19 patients. LAS VEGAS, Aug. 6, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a […]
LAS VEGAS, Aug. 4, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral […]
Houston Methodist Research Institute Professor and Chair of the Department of Cardiovascular Sciences Dr. John Cooke and LSU Health Shreveport Vice Chancellor Dr. Alan Kaye Join the JanOne Team LAS VEGAS, July 30, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing […]
Dr. Flanagan, an accomplished chemist and formulation specialist, leads manufacturing and clinical development of JanOne’s PAD candidate TV1001SR LAS VEGAS, June 25, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build […]
